

References

E-5

1. Kanner AA, Wong ET, Villano JL, et al. Post Hoc analyses of intention-to-treat population in phase III comparison of NovoTTF-100A system versus best physician's choice chemotherapy. *Semin Oncol.* Oct 2014;4(6):S25-S34. PMID25213871
2. Mrugala MM, Engelhard HH, Dinh Tran D, et al. Clinical practice experience with NovoTTF-100A system for glioblastoma: The Patient Registry Dataset (PRiDe). *Semin Oncol.* 2014;41(6):S4-S13. PMID 25213869
3. Wong ET, Lok E, Swanson KD, et al. Response assessment of NovoTTF-100A versus best physician's choice chemotherapy in recurrent glioblastoma. *Cancer Med.* 2014;3(3):592-602. PMID 24574359
4. Yymazal, J, Wong ET. Response Patterns of Recurrent Glioblastomas Treated With Tumor-Treating Fields. *Seminars in Oncology.*2014;41(6):S14-S24.
5. American Association of Neuroscience Nurses (AANN). Care of the adult patient with a brain tumor. *AAHN.*2014;48.
6. Stupp R, Taillibert S, Kanner AA, et al. Maintenance therapy with tumor-treating fields plus temozolomide vs temozolomide alone for glioblastoma: a randomized clinical trial. *JAMA.* 2015;314(23):2535-2543. PMID 26670971
7. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: Central nervous system cancers. Version.1.2016.
8. ECRI Institute. Tumor Treating Fields Therapy (Optune) for Treating Recurrent Glioblastoma. Plymouth Meeting (PA): ECRI Institute;2016 (Emerging Technology Report)
9. Burri S, Gondi V, et al. The evolving role of tumor treating fields in Managing glioblastoma: Guide for Oncologists. *Am J Clin Oncol* 2018;41:191-196.
10. Hayes, Inc. Hayes annual Review. Novocure (Tumor Treatment Fields). Landsdale, PA:Hayes, Inc:2019.
11. Kinzel A, Abbrogio M, Varshaver M, Kirson E. Tumor treating fields for glioblastoma treatment:patient satisfaction and compliance with the second-generation Optune® system. *Clin Med Insights Oncol.* 2019;13:1-7.
12. Trusheim J, Dunbar E, Battiste J, et al. A state-of-the-art review and guidelines for tumor treating fields treatment planning and patient follow-up in Glioblastoma. *CNS Oncol.* 2017;6(1):29–43.